Day 1 Highlights from ASH 2024: Breakthroughs in Sickle Cell Disease and ITP
Curie: The Oncology Brief di Curie: The Platform for HCPs
Note sull'episodio
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.
Dive into Day 1 of ASH 2024 with Curie. In this episode, we discuss key takeaways from groundbreaking studies, including etavopivat’s promising results for sickle cell disease, rilzabrutinib’s potential to transform ITP treatment, and hydroxyurea’s expanded use for managing HbSC.
Parole chiave
OncologysurgeonspodcastTreatmentCancer diagnosticsHCPsDoctorsUSASickle cellITP